Table 4.
Number of K. pneumoniae samples with antimicrobial susceptibility testing (AST) by origin across 18 departments in the years 2008–2016
| Origin of the samples | Tested for | All nosocomial samples (N = 648) | Samples obtained after 2 to 5 hospital days (N = 124) | Samples obtained after 5 hospital days (N = 524) |
|---|---|---|---|---|
| Urine | AM-CL, Amox/AMPb, Quinolones, TMP-SMX | 329 (51%) | 72 (58%) | 257 (49%) |
| CFP, CFT, Gent, MERa, PIP-TZ | 51 (8%) | 12 (10%) | 39 (7%) | |
| Blood | AM-CL, Amox/AMPb, CFP, CFT, Gent, MERa, PIP-TZ, Quinolones, TMP-SMX | 89 (14%) | 9 (7%) | 80 (15%) |
| Respiratory samples | AM-CL, Amox/AMPb, CFP, CFT, Gent, MERa, PIP-TZ, Quinolones, TMP-SMX | 69 (11%) | 16 (13%) | 53 (10%) |
| Wound swabs | AM-CL, Amox/AMPb, CFP, CFT, Gent, MERa, PIP-TZ, Quinolones, TMP-SMX | 22 (3%) | 3 (2%) | 19 (4%) |
| Other | AM-CL, Amox/AMPb, CFP, CFT, Gent, MERa, PIP-TZ, Quinolones, TMP-SMX | 139 (21%) | 24 (19%) | 115 (22%) |
| PIP-TZ | 138 (21%) | 24 (19%) | 114 (22%) |
Abbreviations: Amox amoxicillin, AMP ampicillin, AM-CL amoxicillin-clavulanic acid, CFP cefepime, CFT ceftriaxone, Gent gentamicin, MER meropenem, PIP-TZ piperacillin-tazobactam, TMP-SMX trimethoprim-sulfamethoxazole
aNot included in the models for resistance because only two samples were resistant to Meropenem
bNot included in the models for resistance because all samples were resistant to Amoxicillin/Ampicillin